Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer.

From QIAGEN Manchester Limited 12 Jan 2015

Research findings may lead to new therapeutic target for AML treatment

A study by the Cancer Science Institute of Singapore at the National University of Singapore has found new interactions between two molecules involved in acute myeloid leukaemia (AML), STAT3 and PRL-3, which may offer a new therapeutic target for cancer treatment.

12 Jan 2015

Pellino3 protein may prevent obesity-driven diabetes, find Maynooth University scientists

Maynooth University scientists have identified a protein in the body that may have the potential to prevent the development of obesity-driven diabetes.

12 Jan 2015

Study finds difference between results from IHC and quantitative molecular techniques

The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.

12 Jan 2015

Kidney failure predictors in adolescents: an interview with Dr. Per-Ola Sundin

Diabetes, hypertension and other cardiovascular diseases as well as obesity are some of the markers of risk for kidney failure that we are aware of in adulthood. Markers of risk prior to adulthood for subsequent chronic kidney disease resulting in kidney failure are less well described.

11 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.

8 Jan 2015

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

H&P Labs Inc. announced an agreement with Harvard University and Brigham and Women's Hospital to license two classes of compounds in order to develop an oral drug therapy against Ebola.

8 Jan 2015

Proteomics market expected to experience continual growth

The market for microarrays used to study the workings of proteins are in great demand, according to Kalorama Information. The healthcare market research publisher said "proteomics" instruments, reagents and testing are needed to discover new biomarkers and even new drugs, and that the market for them topped 5 billion dollars in 2013.

8 Jan 2015

Neuroscientists move one step closer to solving how learning and memory work

Researchers at Johns Hopkins have found out how a protein crucial to learning works: by removing a biochemical "clamp" that prevents connections between nerve cells in the brain from growing stronger.

8 Jan 2015

Johns Hopkins-led study offers strategy to eradicate HIV

Luring dormant HIV out of hiding and destroying its last cure-defying holdouts has become the holy grail of HIV eradication, but several recent attempts to do so have failed. Now the findings of a Johns Hopkins-led study reveal why that is and offer a strategy that could form a blueprint for a therapeutic vaccine to eradicate lingering virus from the body.

8 Jan 2015

Canadian Blood Services, OPSEU reach tentative agreement to support employees in Ontario

Today, Canadian Blood Services announced that it has reached a tentative agreement with the Ontario Public Service Employees Union, representing its support employees in Ontario.

8 Jan 2015

Research findings could lead to new drug design for neurological diseases

A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.

8 Jan 2015

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

An international team of researchers has developed a drug delivery technique that utilizes graphene strips as "flying carpets" to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.

7 Jan 2015

New research sheds light on process that controls genes and determines cell fate

For a skin cell to do its job, it must turn on a completely different set of genes than a liver cell — and keep genes it doesn’t need switched off. One way of turning off large groups of genes at once is to send them to “time-out” at the edge of the nucleus, where they are kept quiet. New research from Johns Hopkins sheds light on how DNA gets sent to the nucleus’ far edge, a process critical to controlling genes and determining cell fate.

7 Jan 2015

U-M researchers reveal key gene that may provide potential target for cancer treatment

One of the mysteries in cancer biology is how one protein, TGF-beta, can both stop cancer from forming and encourage its aggressive growth.

6 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.

6 Jan 2015

New findings may lay groundwork of novel treatment for people with Huntington's disease

By adjusting the levels of a key signaling protein, researchers improved motor function and brain abnormalities in experimental animals with a form of Huntington's disease, a severe neurodegenerative disorder.

5 Jan 2015

UT Southwestern researchers target cells' biological clock to kill cancer cells, shrink tumor growth

Cell biologists at UT Southwestern Medical Center have targeted telomeres with a small molecule called 6-thiodG that takes advantage of the cell's 'biological clock' to kill cancer cells and shrink tumor growth.

2 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

OncoGenex executes initial agreement with Teva to regain rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.

31 Dec 2014

Protein News and Research

Further Reading

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

Research findings may lead to new therapeutic target for AML treatment

Pellino3 protein may prevent obesity-driven diabetes, find Maynooth University scientists

Study finds difference between results from IHC and quantitative molecular techniques

Kidney failure predictors in adolescents: an interview with Dr. Per-Ola Sundin

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

H&P Labs announces licensing agreement to develop oral drug therapy against Ebola

Proteomics market expected to experience continual growth

Neuroscientists move one step closer to solving how learning and memory work

Johns Hopkins-led study offers strategy to eradicate HIV

Canadian Blood Services, OPSEU reach tentative agreement to support employees in Ontario

Research findings could lead to new drug design for neurological diseases

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

New research sheds light on process that controls genes and determines cell fate

U-M researchers reveal key gene that may provide potential target for cancer treatment

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

New findings may lay groundwork of novel treatment for people with Huntington's disease

UT Southwestern researchers target cells' biological clock to kill cancer cells, shrink tumor growth

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

OncoGenex executes initial agreement with Teva to regain rights to custirsen

Industry Focus eBook - Protein Analysis (3rd edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics